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The sodium retaining effects of cyclosporine
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Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
The sodium retaining effects of cyclosporine. The effect of chronic
cyclosponne administration on volume regulation was studied in mon-
grel dogs. Dogs received either cyclosporine (20 mg/kg/day p.o.; N = 7)
or vehicle (N = 6) while being maintained on a constant sodium diet.
Dogs had measurement of baseline vasoactive hormones. Daily sodium
excretion was determined. Following eight days of drug administration,
dogs were anesthetized, pre-volume expansion data was collected, and
dogs underwent a one hour, 10% body weight 0.9% saline volume
expansion. Daily sodium balance was +8.6 2.2 mEq in the cyclo-
sporine group versus 0.4 1.8 mEq (P < 0.05) in the control group after
8 days. Prior to acute volume expansion, aldosterone was 22.5 7.1
ng% in the cyclosporine group versus 4.7 0.7 ng% in controls (P <
0.05). ANF was suppressed in the animals receiving cyclosporine. In
response to volume expansion, the cyclosporine group demonstrated an
attenuation of maximum urine flow by 56%, fractional excretion of
sodium by 52%, and electrolyte free water clearance by 75% when
compared to controls (P < 0.05). We demonstrate that chronic cyclo-
sporine administration activates the renin-angiotensin-aldosterone sys-
tem, suppresses circulating ANF, and results in chronic sodium reten-
tion. Additionally, cyclosponne attenuates the natriuretic and diuretic
response to acute volume expansion.
Cyclosporine is an immunosuppressive drug that has been
associated with the development of hypertension in both organ
transplant recipients [1—3] and non-transplant patients [4, 5].
Although cyclosporine is known to have significant nephrotoxic
effects [6], the incidence of cyclosporine associated hyperten-
sion (CAH) substantially exceeds that of the nephrotoxicity,
particularly in cardiac transplant recipients [7]. Therefore,
because hypertension exists in both patients with and without
renal dysfunction, other mechanisms of CAH must exist. The
mechanism or mechanisms responsible for this form of hyper-
tension are unclear [8], although some have suggested that
CAH may be secondary to sodium retention with central
volume expansion [9].
Human studies investigating the effect of cyclosporine on
volume regulation and blood pressure have demonstrated vari-
able results. Some studies have demonstrated suppression of
the renin-angiotensin-aldosterone system (RAAS), extracellular
volume expansion, and a sodium avid state in transplant recip-
ients with CAH [9, 10]. However, other studies have observed
activation of the RAAS [11, 12] with either plasma volume
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reduction [13], or plasma volume expansion [14]. Interpretation
of human studies of CAH is often complicated by intrinsic
disease, co-administration of other drugs including diuretics
and corticosteroids, post-transplant renal or cardiac denerva-
tion, and variably controlled sodium intake.
The current study was designed to provide an integrated
evaluation of the effect of oral cyclosporine on the chronic
regulation of dietary sodium and the excretory response to
acute volume expansion. We hypothesized that cyclosporine
would (1) induce a chronic state of avid sodium retention, and
(2) attenuate the ability of the kidney to acutely excrete sodium
in response to saline volume expansion. The current study was
designed to evaluate the contributory role of cardiac and renal
parameters, and circulatory hormones involved in cyclosporine
induced sodium retention.
Methods
The study was divided into two portions including a chronic
dietary study of eight days duration followed by an acute study
of saline volume expansion. Studies were performed in two
groups of mongrel dogs of either sex weighing 16 to 21 kg.
Before initiation of the chronic study, dogs were surgically
prepared under sodium pentobarbital anesthesia (30 mg/kg) by
placement of an indwelling femoral artery catheter (Baxter
Health Care Corp., Valencia, California, USA). The port of this
catheter was tunneled subcutaneously to the lumbar region and
sutured in place. This catheter was used for the direct measure-
ment of arterial blood pressure and blood collection during the
chronic portion of the study. The dogs received prophylactic
antibiotic treatment with penicillin and streptomycin (Combi-
otica, Pfizer, Inc., New York, USA) and clindamycin (Cleo-
cm®, Upjohn, Kalamazoo, Michigan, USA) pre-operatively and
on the first two days post-operatively. Three days post-opera-
tively dogs were placed in cages equipped with a funneled floor
that allowed for collection of all urine.
All dogs were pair fed and received a constant diet consisting
of 447 g food/day. This included 23.5 mEq Nat/day, and 1.3
kcallg food (Hill's Prescription Diet I/D®, Topeka, Kansas,
USA) and were allowed free access to tap water. Dogs were
then divided into two groups and were pair fed. Group I (N =
7) received oral cyclosporine, 20 mg/kg/day (Sandoz Pharma-
ceuticals, East Hanover, New Jersey) while Group II (N = 6)
received daily cyclosporine vehicle.
Chronic study
Four days after initiating a constant diet, serial baseline data
was collected for two days, averaged, and was termed baseline.
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Serial data collected included arterial pressure and 24-hour
sodium excretion. Data was again collected for two days, after
seven and eight days of cyclosporine or vehicle administration,
averaged and was termed Day eight. Plasma renin activity
(PRA), aldosterone (Aldo), endothelin (ET), and atrial natri-
uretic factor (ANF) concentrations were determined prior to
drug therapy and immediately preceding the acute study.
Acute study
Following the chronic portion of the study, dogs were anes-
thetized with sodium pentobarbital (30 mglkg) and maintained
with supplemental doses as necessary. The trachea was intu-
bated and animals were mechanically ventilated (Harvard Ap-
paratus, Millis, Massachusetts, USA) with supplemental oxy-
gen at 5 liter/mm. A femoral vein was cannulated with two
polyethylene catheters (PE 240, Clay Adams, Parsippany, New
Jersey, USA) for infusion of inulin, saline and supplemental
anesthesia. A femoral artery was cannulated with a polyethyl-
ene catheter (PE 240) for measurement of arterial pressure and
blood sampling. The right internal jugular vein was isolated, and
a 7.5 French balloon tipped thermodilution catheter (Model 93,
l2lA, American Edwards Laboratory, Santa Anna, California,
USA) was advanced into the pulmonary artery. The left kidney
was exposed utilizing a retroperitoneal flank incision. The
ureter was cannulated (PE 200 tubing) for urine collection. A
calibrated electromagnetic flow probe was placed around the
left renal artery and connected to a flowmeter (Model FM 5010,
Carolina Medical Electronics, King, North Carolina, USA) for
continuous monitoring of renal blood flow.
Utilizing one of the femoral vein catheters, each dog received
a priming dose of inulin (Nutritional Biochemicals, Cleveland,
Ohio, USA). A continuous infusion of 1 mI/mm was used in an
effort to achieve a steady-state plasma inulin concentration of
approximately 50 mg!dl. After surgical preparation, the dogs
were suspended in the prone position and allowed to stabilize
for one hour.
Following one hour of equilibration, two 15-minute baseline
clearances were completed. Each clearance consisted of con-
tinuous urine collection, measurement of hemodynamic param-
eters, and withdrawal of arterial blood (30 cc) for hormonal
analysis, electrolyte determination, and inulin concentration.
Blood volume was immediately replaced with 30 cc of normal
saline. The two baseline periods were averaged and termed the
pre-volume expansion period.
Dogs then underwent a 10% body weight intravenous 0.9%
normal saline volume infusion during a 60-minute period utiliz-
ing a femoral vein catheter as previously described by Zimmer-
man et a! [15]. Three 15 minute clearances were collected
ending at 20, 40, and 60 minutes into the volume expansion.
Data from the 60 minute clearance was termed peak volume
expansion (PVE). Following volume expansion, dogs were
allowed to recover, and two additional 15-minute clearances
were obtained ending at 45 and 90 minutes following the
completion of volume expansion.
During each clearance period, heart rate (HR), mean arterial
pressure (MAP), right atrial pressure (RAP), pulmonary artery
pressure (PAP), pulmonary capillary wedge pressure (PCWP),
renal blood flow (RBF), urine flow (V) and hematocrit (Hct)
were measured.
Analyses
Cardiac output (CO) was determined by thermodilution using
a cardiac output computer (model: COM-l, American Edwards
Laboratory, Anasco, Puerto Rico). For each clearance, CO was
determined in triplicate and averaged. During each period,
arterial blood was collected in EDTA tubes (hormone analysis)
and heparinized tubes (electrolyte and inulin concentrations),
immediately placed on ice, and centrifuged at 4°C at 2500 rpm
for 10 minutes. Plasma was separated and stored at —20°C
pending hormonal assay. Arterial plasma and urine for electro-
lyte and inulin determinations were refrigerated at 4°C pending
analysis. Serum and urine inulin concentrations were deter-
mined by the Anthrone method [16]; serum and urine sodium
concentrations were measured by ion-selective probes using a
model E2 A analyzer (Beckman mc, Brea, California, USA).
Extracted ANF [17], extracted ET [18], PRA [19] and aldoste-
rone [20] were measured by radioimmunoassay as previously
described. Cyclosporine concentrations in whole blood were
determined by HPLC [21, 22] with a clinical therapeutic range
of 100 to 300 p.g/ml.
Calculations
Daily sodium balance was calculated as dietary sodium intake
— (urine volume * UNa). Twenty-four-hour creatinine clear-
ance was calculated as (U * 'PCr. Systemic vascular resis-
tance (SVR) was calculated as [(MAP — RAP)(80)I/CO. Renal
vascular resistance (RVR) was calculated as (MAP — RAP)!
RBF. GFR was calculated as the clearance of creatinine
(Ucr * T)/Pcr for the chronic portion of the study and as the
clearance of inulin (U1 * %')fP1 for the acute portion of the
study. Absolute urinary sodium excretion (UNaV) was calcu-
lated as UNa * V. Fractional excretion of sodium (FENJ was
calculated as [(UNa * Pcr)/(Ucr * PNJ] * 100 for the chronic
portion of the study and as [(UNa * P1)/(U1 * PNa)] * 100 for
the acute portion of the study. Filtration fraction (FF) was
calculated as (GFR/RPF) * 100. Renal plasma flow was calcu-
lated as [RBF/(1 — (Hct/100))]. Electrolyte free water clearance
(CeH,O) was calculated as V * [1 — ((UNa + UK)/PNa)l accord-
ing to the method of Rose [23].
Statistics
Data from each group was averaged and expressed as mean
SEM. Student's unpaired 1-test was applied for differences
between groups and the paired 1-test was used for differences
within groups for the chronic portion of the study. Fischer's
ANOVA for multiple comparisons was used to analyze data
within and between groups for the acute portion of the study.
Results were considered significant at P < 0.05.
Results
Chronic study
Table 1 demonstrates the differences in baseline and chronic
blood pressure, renal function, and sodium balance for animals
treated with either cyclosporine or vehicle. Systemic arterial
pressure did not change during the course of the study. UNaV
and FENa were both decreased significantly in the cyclosporine
group but not in the vehicle group. There was no difference in
24-hour creatinine clearance between groups or within groups.
Both groups lost weight throughout the study; however, there
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Table 1. Hemodynamic and renal responses to chronic cyclosporine
therapy
Baseline (Day 0) Day 8
143 4
ill 6
126 4
48.9 3.5
0.4 1.8
16.5 1.2
0.25 0.02
____________________________________________
17.5 0.5
Data expressed as mean SEM; N = 7 Group I, N = 6 Group II.
Abbreviations are: BP, blood pressure; MAP, mean arterial pressure;
Na balance, 24-hour sodium balance; U Na V, absolute urinary
sodium excretion; FENa, urinary fractional excretion of sodium.a P < 0.05 baseline vs. day 8b P < 0.05 Group I vs. Group II
was no difference between groups. No gastrointestinal intoler-
ance was observed in either group before or during drug
administration. The cumulative sodium balance demonstrated a
natriuretic response during the first three days of cyclosporine
administration (Fig. 1). After this point, overall sodium balance
became progressively positive and on day eight the daily
positive sodium balance was statistically significant in the
cyclosporine treated animals (Fig. 2). The 24-hour trough whole
blood cyclosporine concentration on day seven was 285 114
g/ml.
Fig. 2. Daily sodium balance prior to and after 8 days of vehicle (black
bars) or cyclosporine (hatched bars) administration. Sodium balance
was significantly positive in the cyclosporine treated animals. * D
0.05 baseline vs. day 8; t P < 0.05 cyclosporine vs. vehicle.
Table 2 illustrates the endocrine response to chronic cyclo-
sporine. PRA increased from 1.9 0.7 to 5.0 1.4 (ng/ml/hr) in
the cyclosporine group after eight days of cyclosporine admin-
istration while it decreased in the vehicle group from 4.1 0.9
to 1.0 0.4 (ng/ml/hr) (P < 0.05). After eight days of cyclo-
sponne administration, aldosterone was activated in the cyclo-
sporine group 22.5 7.1 (ng%), and was significantly greater
than the vehicle group 4,7 0.7 ng% (P < 0.05). ANF was
suppressed with chronic administration in the cyclosporine
treated group only. There was no difference in plasma ET levels
either between or within groups (Table 2).
Acute study
Table 3 demonstrates the hemodynamic response to acute
volume expansion in the dogs receiving cyclosporine and
vehicle. Heart rate did not change in either group during the
course of the acute study. MAP was unchanged during volume
expansion in both groups. CO, PAP, PCWP, and RAP showed
no difference between groups, but all showed significant rises at
PVE and significant differences from PVE during recovery in
both groups. SVR decreased significantly in both groups with
PVE. During recovery SVR rose to significantly higher than
pre-volume expansion in the cyclosporine treated group and to
pre-volume expansion levels in the vehicle group.
Table 4 illustrates the renal response to acute volume expan-
sion. At pre-volume expansion V, FENa, UNAV, and Ce20
were all significantly less in the cyclosporine treated dogs than
in vehicle treated controls. There was no difference between
groups in GFR at pre-volume expansion or at PVE. V, FENa,
UNa*:T, and Ce20 all demonstrated a significantly attenuated
increase in response to volume expansion in the cyclosporine
treated group compared to the vehicle group (Figs. 3, 4, 5).
GFR remained statistically unchanged during acute volume
expansion in both groups. RBF demonstrated no difference
between groups at baseline, but increased significantly at PVE
Group I (cyclosponne)
Systolic BP mm Hg
Diastolic BP mm Hg
MAP mm Hg
24-Hr creatinine clearance ml/min
Na balance mEq
U Na. V Eq/min
FENa %
Weight kg
Group H (vehicle)
Systolic BP mm Hg
Diastolic BP mm Hg
MAP mm Hg
24-Hr creatinine clearance mi/mm
Na balance mEq
U Na V p.Eq/min
FEND %
Weight kg
144 2
113 4
127 3
45.7 5.5
8.6 22a,b
10.5 16a.b
0.17 002a.b
17.5 0.6
156 8
104 6
126 4
47.8 4.4
—2.9 2.6
18.0 1.7
0.29 0.04
18.5 0.6
145 4
104 5
124 4
39.7 7.7
3.0 2.7
13.5 1.9
0.26 0.03
18.2 0.5
Fig. 1. Cumulative sodium balance during 8 days of vehicle (black
bars) or cyclosporine (hatched bars) administration.
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Table 2. Endocrine response to chronic cyclosporine therapy and 10% acute volume expansion
Baseline Pre-vol. Volume expansion Recovery
(day—I/O) expansion (peak) (+90)
Group I (cyclosporine)
PRA ng/mi/hr 1.9 0.7 5.0 1.4C 0.6 02b 2.1 12b
Aldo ng/di 3.7 1.2 22.5 7.1C 6.8 2.1' 20,46 11.O61
ANF pg/mI 67.2 10.3 26.0 7.2° 137.1 25.5" 41.0 11.0"
ETpg/ml 11.3 3.1 13.1 2.4 7.6 0.9" 9.4 1.3"
Group II (Vehicle)
PRA ng/mi/hr 4.1 0.9 0.98 0.36a 0.23 0.09 2.4 1.9
Aldo ng/dl 2.6 0.6 4.7 0.7° BDL(<2.5) 0.0" 2.0 1.5'-'
ANF pg/mi 50.0 19.5 37.6 9.7 137.2 47.4 91.6 47.7
ETpg/mi 8.6 0.8 9.2 0.7 7.4 0.8 9.2 0.75
Data are expressed as mean 5EM; N = 7 Group I, N = 6 Group II. Abbreviations are: BDL, below detectable limits; PRA, plasma renin
activity; Aldo, aldosterone; ANF, atrial natriuretic factor; ET, plasma endothelin.a P = <0.05 Pre-volume expansion vs. baselineb P = <0.05 Peak volume expansion (PVE) vs. Pre-volume expansionP = <0.05 Group I vs. Group II
"P = <0.05 volume expansion vs. recovery
Table 3. Hemodynamic response to 10% acute volume expansion
following chronic cyclosporine/vehicle administration
Volume
Pre-vol. expansion Recovery
expansion (peak) (+90 mm)
Group I (cyclosporine)
HRbpm 128±11 122 110±12
MAPmmHg 118±6 123 7
CO liter/mm 2.85 0.23 4.61 0.36° 2.22 021b
PAP mm Hg 13 1 19 ia 13 1b
RAP mm Hg —2 1 3 1° —2 1"
PCWP mmHg 3 1 10 ia 2
SVR dyn - sec/cm5 3500 230 2077 143° 4562 483a,b
Group H (vehicle)
HRpbm 126 12 122 9 115 8
MAP mm Hg 113 6 113 5 118 8°"'
CO liter/mm 2.50 0.13 4.68 0.23° 2.40 0.17"
PAP mm Hg 13 1 18 ia 12 0a,b
RAPmmHg —2±0 3±1 —2±0
PCWPmmHg 3±1 8±1' 20b
SVR dyn . sec/cm5 3726 158 1902 I27 4120 421"
Data expressed as mean SEM; N = 7 Group I, N = 6 Group II.
Abbreviations are: PAP, pulmonary artery pressure; PCWP, pulmonary
capillary wedge pressure; SVR, systemic vascular resistance; bpm,
beats per minute.
a P = <0.05 vs. pre-volume expansionb P <0.05 volume expansion vs. recovery
P = <0.05 cyclosporine vs. vehicle
in the cyclosporine treated dogs (Fig. 6). FF and RVR tended to
be higher at pre-volume expansion in the cyclosporine group.
RVR was significantly diminished by volume expansion only in
the vehicle animals.
Table 2 also demonstrates the endocrine response to acute
volume expansion. The elevated PRA in the cyclosporine group
was suppressed by acute volume expansion. Despite volume
expansion, aldosterone failed to be completely suppressed in
the cyclosporine treated group. ANF increased to a similar
level in both groups at PVE. ET showed no difference between
groups before, during, or following volume expansion. In the
cyclosporine treated group ET was statistically suppressed at
PVE and recovery compared to pre-volume expansion.
Pre-vol.
Volume
expansion Recovery
expansion (peak) (+90 mm)
Group I (cyclosporine)
Urine flow mI/mm 0.1 0.0 4.2 1.1 0.3°"
FENa % 0.43 O.ISC 9.92 2.lsa,C 5.57 1.34°"
U Na- V SEq/mn 14.0 49C 535.6 84,9C 227.5 550a.b
GFR mi/mn 31.9 3.4 38.9 7.0 27.4 4.6
RBF mi/mn 153 35 206 43° 137 37b
RVR (R.U.) 1.11 0.31 0.82 0.26 1.24 0.25
CCH2O mi/mn
FF%
—0.09 0.03
53.6 16.3
0.38 0.2l°° —0.60 015a.b
31.0 11.9 31.3 7.6
Group II (vehicle)
Urine flow mi/mn 0.3 0.1 9.6 2.0° 1.4 02b
FENa % 2.10 0.79 20.80 3.11° 8.28 220a.b
U Na- V p.Eq/mn 57.6 13.6 1151.0 259.0° 275 29.2"
GFR mi/mn 26.0 3.4 36.5 5.3 28.3 5.3
RBF mi/mn 150 17 217 31° 166 27b
RVR (RU.) 0.83 0.13 0.57 o.lo 0.89 0.23"
CeH , mi/mn
FF
—0.15 0.06
25.2 6.7
1.53 0.29a —0.64 0.09"
20.5 4.2° 26.4 9.4
Data expressed as mean SEM; N = 7 Group I, N = 6 Group II.
Abbreviations are: FENa, urinary fractional excretion of sodium; U
Na. V, absolute urinary excretion of sodium; GFR, glomerular filtra-
tion rate; RBF, renal blood flow; RPF, renal plasma flow; RVR, renal
vascular resistance; C°H,o, electrolyte free water clearance; FF, filtra-
tion fraction; R.U., resistance units.
a P = <0.05 vs. pre-volume expansionb P = <0.05 volume expansion vs. recovery
C p = <0.05 cyclosporine vs. vehicle
Discussion
The current study was designed to investigate the effects of
cyclosporine administration on the chronic and acute regulation
of sodium and volume homeostasis. This study provides com-
plete hemodynamic, renal, and hormonal characterization of
the effects of cyclosporine with both placebo and diet control.
The effect of cyclosporine on volume regulation and neuro-
humoral activity has previously been incompletely character-
ized. We demonstrate that chronic cyclosporine administration
results in active sodium retention with associated activation of
Table 4. Renal response to 10% acute volume expansion following
chronic cyclosporine/vehicle administration
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L..........Volume I Recovery I
expansion
Fig. 3. Urine flow rate before, during, and following acute saline
volume expansion in vehicle treated (open box) and cyclosporine
treated (black box) animals. * P < 0.05 vs. pre-volume expansion; t P
<0.05 cyclosporine vs. vehicle.
30
Time, minutes
Fig. 4. Fractional excretion of sodium, before, during, and following
acute saline volume expansion in vehicle treated (open box) and
cyclosporine treated (black box) animals. * P < 0.05 vs. pre-volume
expansion; t P < 0.05 cyclosporine vs. vehicle.
Time, minutes
Fig. 5. Electrolyte free water clearance, before, during, and following
acute saline volume expansion in vehicle treated (open box) and
cyclosporine treated (black box) animals. * P < 0.05 vs. pre-volume
expansion; t P < 0.05 cyclosporine vs. vehicle.
0
L....Volume I Recovery I
expansion
Time, minutes
Fig. 6. Renal blood flow (A) and glomerular filtration rate (B) before,
during, and following saline volume expansion in vehicle (open box)
and cyclosporine (black box) treated animals. * P < 0.05 vs. pre-
volume expansion.
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the RAAS and suppression of circulating ANF. Furthermore,
there was an attenuated natriuretic and diuretic response to the
acute challenge of intravenous volume expansion in the cyclo-
sporine group which resulted from enhanced tubular reabsorp-
tion of sodium.
Possible reasons for enhanced sodium reabsorption include
direct renal tubular, vascular, and hormonal factors which may
become altered with cyclosporine administration. Cyclosporine
is known to be nephrotoxic [24, 251, and decreased FENa has
been suggested to be an early marker of cyclosporine nephro-
toxicity [26, 271. While the degree of morphological change is
minimal [281, renal impairment may be primarily due to the
vasoactive effects of cyclosporine [29, 301. Although renal
toxicity has been demonstrated with cyclosporine-mediated
afferent vasoconstriction [28, 31, 32], increased RVR [13,
33—35], and consequent GFR decrease, this can only partially
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explain our observed attenuation of natriuresis and diuresis.
While we observed a tendency for cyclosporine to increase
RVR, this change did not achieve statistical significance. Our
data demonstrates a tendency for GFR to be higher in the
cyclosporine treated dogs and RBF to be virtually identical
between groups after eight days of cyclosporine or vehicle
administration. The GFR may have been maintained in this
situation by efferent arteriolar vasoconstriction, with increased
FF. While overall renal blood flow was similar in both groups,
we did not evaluate the intrarenal distribution of blood flow.
Sodium regulating hormones may account for the decreased
sodium excretion observed in this study. This may represent an
aldosterone effect since this hormone (1) was strongly activated
in the cyclosporine group, and (2) failed to be completely
suppressed at PVE. Cyclosporine administration resulted in
activation of PRA. ANF was suppressed by chronic cyclospo-
rifle administration, and tended to be higher in the control dogs.
At baseline there was no statistical difference in sodium
balance between the two groups. The observed sodium reten-
tion and activation of sodium retaining mechanisms in the
cyclosporine group were not a response to sodium depletion
prior to the experiment. There was no evidence that either
group of dogs was volume depleted at the onset of the study.
Blood pressure, FENa, UNaV, and the volume sensitive hor-
mones (that is, PRA, aldosterone, ANF) were not different
between groups. Furthermore, the observed sodium retention
did not occur in the pair fed control group.
This study supports and extends previous studies reporting
cyclosporine mediated activation of the RAAS [11, 12, 36, 371
and is consistent with the observation that CAH may be linked
to cyclosporine-mediated sodium retention [9]. While others
have observed suppression of the RAAS by cyclosporine, this
finding may reflect expansion of the extracellular fluid volume
[10] and may be a late manifestation of the disease process
involved in CAH. In the current study, sodium retention and
activation of the RAAS was observed only in the cyclosporine
treated animals and not in the diet matched controls. By
examining the daily cumulative sodium balance there appears to
be a unique biphasic response to cyclosporine. During the first
three days of cyclosporine administration, there appeared to be
a relative natriuresis with negative sodium balance (Fig. 1), and
a tendency toward intravascular volume depletion. This may
stimulate activation of the RAAS which in the later period
becomes relatively autonomous.
While it was not the objective of this study to directly
investigate the mechanisms of renin and aldosterone activation,
it is important to recognize that ANF acts as a potent inhibitor
of renin and aldosterone and has been reported to be able to
reverse the nephrotoxic effects of cyclosporine [38]. Suppres-
sion of ANF in a model of low atrial pressure congestive heart
failure has been associated with renin activation and sodium
retention [39]. In the current study, a reduction in ANF may
partially account for the observed activation of the RAAS and
the antinatriuretic state. The reduction in ANF may be the
result of either decreased secretion or increased metabolism.
There does not appear to have been a reduction in the hemo-
dynamic stimulus for ANF secretion since atrial pressure after
eight days was nearly identical in both groups of animals
studied. Furthermore, in response to volume expansion, atrial
pressure and ANF rose in parallel. It has been reported that
cyclosporine induces activation in renal tubular metabolism in
the S3 segment of the nephron [40, 41]. This area is rich in
neutral endopeptidase activity, and its activation would in-
crease the clearance and decrease the circulatory levels of
ANF.
The effect of cyclosporine on circulating endothelin (ET) has
been an area of recent interest. Acute administration with large
doses of cyclosporine have variably been associated with either
no change or an increase in circulating ET [42]. In the first week
following liver transplantation, circulating ET is increased [43].
However, this time period is associated with many hemody-
namic and physiologic alterations, and the isolated effect of
cyclosporine is difficult to evaluate. In stable cardiac transplant
recipients, ET is not different in cyclosporine versus non-
cyclosporine treated subjects [44]. While local intrarenal endo-
thelin was not evaluated, the current study is consistent with
the observation that cyclosporine does not increase circulating
endothelin.
We conclude that cyclosporine administration results in
active sodium retention. This is due in part to (1) activation of
the renin-angiotensin-aldosterone system, and (2) suppression
of circulating ANF.
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